BD Biosciences has launched its line of BD Purecoat cell culture surfaces designed to help improve cell performance and assay reproducibility.
The range is intended for use by life-science researchers in the pharmaceutical and biotechnology industries, as well as the academic research community.
Carolyn James, the company's country business leader for the UK and Ireland, said: 'Today's life-science researchers are increasingly using primary cells, transfected cells and stem cells in research and drug-discovery assays.
'These fastidious cells often require optimised cell culture surfaces to achieve reproducible and consistent assay results,' she added.
In basic cell culture research, scientists are looking for methods to improve cell growth and reduce or remove the serum in culture media to save costs and reduce variability.
BD Purecoat surfaces improve cell attachment, increase proliferation and enhance recovery from freeze-thaw for a variety of primary, transfected and transformed cells in serum-reduced or serum-free culture conditions.
This allows researchers to produce more cells in better-defined conditions, according to the company.
In cell-based drug-discovery screening, scientists often culture transfected and cryopreserved division-arrested cells for use in cell-based screening assays.
The strong attachment of these cells is said to be critical to achieving a robust assay and cell monolayer consistency is directly related to reproducible assay results.
The company claims that BD Purecoat surfaces maintain the integrity of the cell monolayer, offering better consistency in cell-based assays versus standard tissue-culture surfaces.
The BD Purecoat amine and carboxyl surfaces utilise a proprietary thin-film coating technology to produce a uniform, functionalised surface for cell culture.
